7 patents
Utility
Treatment of Viral Infection by Apheresis
10 Mar 22
The invention is directed to the treatment of COVID-19 patients by withdrawing SARS-CoV-2 viral particles from the patient's circulation by apheresis using a binding agent in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles.
Isaac ELIAZ
Filed: 10 Sep 20
Utility
Plasmapheresis Device
13 May 21
A plasmapheresis device includes a column or other flow mechanism in which plasma lows following separation of the plasma from cellular components like blood cells, platelets and the like.
ISAAC ELIAZ
Filed: 11 Jan 21
Utility
GALECTIN-3 Plasmapheresis Therapy
6 Jan 21
A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties.
ISAAC ELIAZ
Filed: 8 Aug 20
Utility
GALECTIN-3 Plasmapheresis Therapy
15 Jul 20
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles.
Isaac ELIAZ
Filed: 21 Mar 20
Utility
GALECTIN-3 Plasmapheresis Therapy
18 Mar 20
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles.
ISAAC ELIAZ
Filed: 17 Nov 19
Utility
GALECTIN-3 Plasmapheresis Therapy
18 Mar 20
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles.
ISAAC ELIAZ
Filed: 17 Nov 19
Utility
GALECTIN-3 Plasmapheresis Therapy
11 Mar 20
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles.
ISAAC ELIAZ
Filed: 17 Nov 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first